Why attend the Antigen Specific Immune Tolerance Digital Summit (ASIT)?
Learn from representatives from big Pharma, Biotech and Academia at the Antigen-Specific Immune Tolerance Digital Summit 2021 and join a thought-leading platform dedicated to overcoming the complex challenges associated with antigen-specific immunotherapies.
Built with an industry-focused agenda, join to hear from our expert speaking faculty and gain insight from 20+ experts from Harvard Medical School, Selecta Biosciences, Toleranzia, Apitope, ImCyse and many more.
Address the key challenges currently impeding drug development for tolerance inducing therapeutics. Incorporating insights from industry-leading speakers, this conference will delve into the key target discovery, tolerance delivery, and regulatory hurdles that must be addressed for ASIT therapeutics to fulfill their full commercial potential.
This is your comprehensive guide to define your drug development path for 2021. Don’t miss out on your chance to network with industry leaders and join the only industry forum dedicated to driving the progression of your drug development towards the clinic.
- Explore across learning opportunities and benchmark the progress of your antigen specific drug development against progress in the fields of allergy, oncology and transplantation and gain insights from Epivax and The Immune Tolerance Network
- Enhance your clinical trial success rate by examining and evaluating current tolerance delivery practices with insights from Merck, Anokion & AdiTxt
- Examine the fundamental biological controls that determine effective induction of regulatory T cells by better understanding how to successfully induce tolerance with insights from Novo Nordisk, Eli Lilly & Clarivate Analytics
- Review clinical trial readouts for ASIT therapeutics and explore the fundamental mechanisms that lie behind successful and unsuccessful clinical trial delivery with insights from Cour Therapeutics, Selecta Biosciences & Apitope